Percutaneous thermal ablation combined with transcatheter arterial chemoembolization for hepatitis C virus-related hepatocellular carcinoma: Efficacy and survival

被引:1
作者
Sun, Yu [1 ]
Zhang, Honghai [1 ]
Long, Jiang [1 ]
Zhang, Yonghong [1 ]
Zheng, Jiasheng [1 ]
Yuan, Chunwang [1 ]
机构
[1] Capital Med Univ, Beijing Youan Hosp, Liver Dis & Canc Intervent Therapy Ctr, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
hepatocellular carcinoma; transcatheter arterial chemoembolization; percutaneous thermal ablation; overall survival; recurrence; prognosis; ALBUMIN-BILIRUBIN GRADE; RADIOFREQUENCY ABLATION; TRANSARTERIAL CHEMOEMBOLIZATION; MICROWAVE ABLATION; LIVER-FUNCTION; RECURRENCE; STAGE; CHINA;
D O I
10.3389/fonc.2022.978614
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveThe aim of this study was to investigate the efficacy and survival of Hepatitis C virus (HCV) -related hepatocellular carcinoma (HCC) undergoing percutaneous thermal ablation combined with transcatheter arterial chemoembolization (TACE). MethodsA total of 83 HCV-related HCC patients who were treated with percutaneous thermal ablation combined with TACE were retrospectively analyzed. The demographic and clinical data were collected. The overall survival (OS) and recurrence free survival (RFS) rates were assessed by the Kaplan-Meier method. Univariate and multivariate Cox regression analysis was used to assess independent risk factors of OS and RFS. Results92.8% patients (77/83) and 96.6% (170/176) tumor lesions achieved complete response (CR) 1 month after all treatment, and 10.8% (9/83) patients had minor complications. The median OS was 60 months (95% confidence interval (CI)= 48.0-72.0), and the 1-, 2-, 3-, 5- and 10-year cumulative OS rates were 94%, 78.3%, 72.3%, 43.4% and 27.5%, respectively. The cumulative RFS rates at 1-, 2-, 3- and 5-year were 74.7%, 49.3%, 30.7% and 25.3%, respectively. Sex (HR =0.529, P=0.048), ablation result (HR=5.824, P=0.000) and Albumin-bilirubin (ALBI) score (HR=2.725, P=0.011) were independent prognostic factors for OS. Alpha-fetoprotein (AFP) (HR =2.360, P = 0.005) and tumor number(HR=2.786, P=0.000) were independent prognostic factors for RFS. ConclusionsPercutaneous thermal ablation combined with TACE is a safe and effective treatment for HCV-related HCC. Sex, ablation result and ALBI are significant prognostic factors for OS. AFP and tumor number are significant prognostic factors for RFS.
引用
收藏
页数:9
相关论文
共 27 条
[1]   Nomogram based on albumin-bilirubin grade to predict outcome of the patients with hepatitis C virus-related hepatocellular carcinoma after microwave ablation [J].
An, Chao ;
Li, Xin ;
Yu, Xiaoling ;
Cheng, Zhigang ;
Han, Zhiyu ;
Liu, Fangyi ;
Yu, Jie ;
Liang, Ping .
CANCER BIOLOGY & MEDICINE, 2019, 16 (04) :797-810
[2]   Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients [J].
Cabibbo, Giuseppe ;
Celsa, Ciro ;
Calvaruso, Vincenza ;
Petta, Salvatore ;
Cacciola, Irene ;
Cannavo, Maria Rita ;
Madonia, Salvatore ;
Rossi, Margherita ;
Magro, Bianca ;
Ini, Francesca ;
Distefano, Marco ;
Larocca, Licia ;
Prestileo, Tullio ;
Malizia, Giuseppe ;
Bertino, Gaetano ;
Benanti, Francesco ;
Licata, Anna ;
Scalisi, Ignazio ;
Mazzola, Giovanni ;
Di Rosolini, Maria Antonietta ;
Alaimo, Giuseppe ;
Averna, Alfonso ;
Cartabellotta, Fabio ;
Alessi, Nicola ;
Guastella, Salvatore ;
Russello, Maurizio ;
Scifo, Gaetano ;
Squadrito, Giovanni ;
Raimondo, Giovanni ;
Trevisani, Franco ;
Craxi, Antonio ;
Di Marco, Vito S. ;
Camma, Calogero .
JOURNAL OF HEPATOLOGY, 2019, 71 (02) :265-273
[3]   Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma [J].
Cho, Ju-Yeon ;
Choi, Moon Seok ;
Lee, Gil Sun ;
Sohn, Won ;
Ahn, Jemma ;
Sinn, Dong-Hyun ;
Gwak, Geum-Youn ;
Paik, Yong-Han ;
Lee, Joon Hyeok ;
Koh, Kwang Cheol ;
Paik, Seung Woon .
CLINICAL AND MOLECULAR HEPATOLOGY, 2016, 22 (04) :477-486
[4]   Percutaneous microwave ablation for HCV-related hepatocellular carcinoma: Efficacy, safety, and survival [J].
Darweesh, Samar K. ;
Gad, Amal A. .
TURKISH JOURNAL OF GASTROENTEROLOGY, 2019, 30 (05) :445-453
[5]   Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis [J].
El-Serag, Hashem B. ;
Rudolph, Lenhard .
GASTROENTEROLOGY, 2007, 132 (07) :2557-2576
[6]   Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis [J].
Glassberg, Mrudula B. ;
Ghosh, Sudip ;
Clymer, Jeffrey W. ;
Qadeer, Rana A. ;
Ferko, Nicole C. ;
Sadeghirad, Behnam ;
Wright, George W. J. ;
Amaral, Joseph F. .
ONCOTARGETS AND THERAPY, 2019, 12 :6407-6438
[7]   Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis [J].
Iyer, Janaki K. ;
Kalra, Mamta ;
Kaul, Anil ;
Payton, Mark E. ;
Kaul, Rashmi .
WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (37) :6802-+
[8]   Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade [J].
Johnson, Philip J. ;
Berhane, Sarah ;
Kagebayashi, Chiaki ;
Satomura, Shinji ;
Teng, Mabel ;
Reeves, Helen L. ;
O'Beirne, James ;
Fox, Richard ;
Skowronska, Anna ;
Palmer, Daniel ;
Yeo, Winnie ;
Mo, Frankie ;
Lai, Paul ;
Inarrairaegui, Mercedes ;
Chan, Stephen L. ;
Sangro, Bruno ;
Miksad, Rebecca ;
Tada, Toshifumi ;
Kumada, Takashi ;
Toyoda, Hidenori .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) :550-U45
[9]   The role of preoperative albumin-bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma [J].
Kornberg, Arno ;
Witt, Ulrike ;
Schernhammer, Martina ;
Kornberg, Jennifer ;
Mueller, Katharina ;
Friess, Helmut ;
Thrum, Katharina .
JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (07) :1126-1136
[10]   Resection and liver transplantation for hepatocellular carcinoma [J].
Llovet, JM ;
Schwartz, M ;
Mazzaferro, V .
SEMINARS IN LIVER DISEASE, 2005, 25 (02) :181-200